Skip to content

Therapeutic Mechanisms and Neural Substrates of Transdiagnostic Cognitive Behavioral Therapy for Emotional Disorders (Continuation of an Ancillary Study to an Existing Trial)

Therapeutic Mechanisms and Neural Substrates of Transdiagnostic Cognitive Behavioral Therapy for Emotional Disorders (Continuation of an Ancillary Study to an Existing Trial) - JUNP MRI study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000058549
Enrollment
200
Registered
2025-07-22
Start date
2023-06-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders Depressive Disorders

Interventions

Unified Protocol with Treatment As Usual Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more a

Sponsors

National Center of Neurology and Psychiatry, Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) DSM-IV or DSM-5 diagnosis of Major Depressive Disorder, Dysthymia, Depressive Disorder Not Otherwise Specified, Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Agoraphobia Without History of Panic Disorder, Social Phobia(Social Anxiety Disorder), Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder Not Otherwise Specified assessed by SCID or M.I.N.I.. b) Depressive and anxiety symptoms is mild or more severe (GRID-HAMD >= 8). c) Ages 20 years or older, and 65 years or younger at screening. d) Subjects who give full consent in the participation of the study.

Exclusion criteria

Exclusion criteria: a) No alcohol or substance use disorder in 6 months prior to the screening assessed by SCID or M.I.N.I.. b) No current manic episode or current schizophrenia and other psychotic disorders at baseline assessed by SCID or M.I.N.I.. c) No serious suicidal ideation at baseline (GRID-HAMD Item3 severity is 3 or higher.) d) No life-threatening, severe or unstable physical disorders or major cognitive deficits at baseline. e) Evidence of unable to participate half or more of the intervention phase. f) No structured psychotherapy during at baseline. g) Other relevant reason decided by the investigators.

Design outcomes

Primary

MeasureTime frame
GRID-Hamilton Depression Rating Scale-17 (GRID-HAMD) [Time Frame: 21 weeks]

Secondary

MeasureTime frame
Assessment of Therapeutic Mechanisms and Processes (Patient-Reported Questionnaires for Therapeutic Mechanisms) Neuroticism (EPQR-S) [Time Frame: 21 weeks] Anxiety Sensitivity (ASI) [ Time Frame: 21 weeks] Emotion Regulation Skills (ERSQ) [Time Frame: 21 weeks] Emotional Exposure Scale (EES) [Time Frame: 21 weeks] Therapeutic Principles of the Unified Protocol (TRUP) [Time Frame: 21 weeks] (Process Measures) Credibility/Expectancy Questionnaire (CEQ) : Rated by both therapist and patient [Time Frame: 21 weeks] Session Rating Scale (SRS) : Rated by both therapist and patient [Time Frame: 21 weeks] Homework Compliance Scale (HCS) : Rated by therapist [Time Frame: 21 weeks] Therapist Adherence Scale (TAS) : Rated by supervisors and independent raters [Time Frame: 21 weeks] Neuroimaging Data 3-Tesla MRI: Resting-state fMRI and T1-weighted 3D structural images [Time Frame: 21 weeks]

Countries

Japan

Contacts

Public ContactMasaya Ito

National Center of Neurology and Psychiatry National Center of Cognitive-Behavior Therapy and Research

masaya-ito@umin.ac.jp+81-42-341-2712(3605)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026